Study of Cemiplimab for Early-Stage Cutaneous Squamous Cell Carcinoma
This study is investigating cemiplimab, a medication that helps your immune system fight cancer, for adults with early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by targeting a protein called PD-1. The study aims to see how well cemiplimab, when injected directly into the tumor, compares to standard surgery. Researchers will also look at any side effects. You may be eligible if you are an adult with a CSCC tumor between 1 cm and 2 cm on your head, neck, hand, or lower leg. The study plans to enroll 369 participants, but its current status is unclear.
- Study design
- This interventional study plans to enroll 369 participants. It compares cemiplimab injections to standard surgery.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for Event-Free Survival for up to 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
At a glance
Conditions
Where it's being run
52 sites across 30 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Event-Free Survival (EFS) as assessed by the investigatorUp to 1 year
- EFS as assessed by the investigatorUp to 3 years